Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
R BrunoL B Sheiner

Abstract

The population pharmacokinetic/pharmacodynamic (PK/PD) approach was prospectively integrated in the clinical development of docetaxel to assess the PK profile in a large population of patients and investigate systemic exposure as a prognostic factor for clinical outcome. PK analysis was performed at first course in 24 phase II studies of docetaxel monotherapy using four randomized limited-sampling schedules. Bayesian estimates of clearance (CL), area under the concentration-time curve (AUC), and peak and duration of plasma levels greater than threshold levels were used as measures of exposure. PD data included for efficacy, response rate, time to first response, and time to progression (TTP) in breast cancer and non-small-cell lung cancer (NSCLC), and for toxicity, grade 4 neutropenia, and febrile neutropenia at first course and time to onset of fluid retention. PK/PD analysis was conducted using logistic and Cox multivariate regression models. PK protocol implementation was successful. Most of the patients registered (721 of 936, 77%) were sampled and 68% were assessable for PK (640 patients). First-course docetaxel AUC was a significant predictor (P = .0232) of TTP in NSCLC (n = 151). Docetaxel CL was a strong independent pre...Continue Reading

Citations

Oct 8, 1998·Pathology Oncology Research : POR·P CanalJ Robert
Jun 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N YamamotoN Saijo
Feb 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J AlexandreE Cvitkovic
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A SparanoW C Wood
Dec 12, 2001·British Journal of Clinical Pharmacology·G ToffoliM Boiocchi
Feb 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Albert J ten TijeSharyn D Baker
Mar 18, 2006·Cancer Science·Hironobu MinamiHirofumi Fujii
Jan 13, 2006·Cancer Immunology, Immunotherapy : CII·Rodney A PrellKarin Jooss
Mar 3, 2006·Clinical Pharmacokinetics·Sharyn D BakerJaap Verweij
Dec 13, 2006·Anti-cancer Drugs·Frederike K EngelsJaap Verweij
Oct 3, 2007·Cancer Chemotherapy and Pharmacology·Wei-Peng YongBoon-Cher Goh
Nov 3, 2007·The Journal of Clinical Investigation·Antonius E van HerwaardenAlfred H Schinkel
Oct 18, 2007·The Korean Journal of Internal Medicine·Yoon Ho KoJin Hyoung Kang
Apr 26, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Véronique Loustaud-RattiElisabeth Vidal
May 30, 2008·Clinical Pharmacology and Therapeutics·S D BakerA Sparreboom
Mar 30, 2010·Cancer Science·Yasunao KogashiwaNaoyuki Kohno
Dec 3, 2009·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Kazuhiro OzawaHitoshi Sato
Jun 24, 2011·Breast Cancer Research and Treatment·K KawaguchiUNKNOWN Japan Breast Cancer Research Group (JBCRG)
Jun 23, 2011·British Journal of Clinical Pharmacology·Belén ValenzuelaJuan José Pérez-Ruixo
Nov 10, 2012·Experimental and Therapeutic Medicine·Kyu-Sik KimYoung-Chul Kim
Sep 27, 2013·Clinical Pharmacokinetics·Andrew K L GoeyJan H M Schellens
Jul 24, 2014·Cancer Chemotherapy and Pharmacology·Toshikado KanetaYasutsuna Sasaki
Feb 1, 2014·Japanese Journal of Clinical Oncology·Kazuhiko YamadaTomoaki Hoshino
Oct 12, 2014·Cancer Chemotherapy and Pharmacology·Devalingam MahalingamAlain C Mita
Nov 15, 2014·Expert Opinion on Drug Metabolism & Toxicology·Markus Joerger
Aug 25, 2015·Cancer Chemotherapy and Pharmacology·Jai N Patel, Apostolos Papachristos
Nov 22, 2015·Cancer Chemotherapy and Pharmacology·Markus Joerger
Oct 27, 2015·Digestive Diseases and Sciences·Jennifer L Horsley-SilvaHugo E Vargas

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.